Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an open single-arm clinical study aimed at evaluating the safety and tolerance of
allogeneic γ9δ2 T cell injection in the treatment of patients with recurrent hematologic
tumors after allogeneic hematopoietic stem cell transplantation.